Orphazyme: Regulatory progress
Research Note
2019-12-19
08:43
During November and December, Orphazyme has received both breakthrough therapy designation and Fast Track designation by FDA in two separate indications for arimoclomol.
AH
Anders Hedlund
Disclosures and disclaimers